Observational studyJournal of diabetes2026
Multimorbidity and the Number of Conditions Increase With the Duration of Type 1 Diabetes and Associate With Increased Mortality.
Observational study in Journal of diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMultimorbidity in type 1 diabetes has previously not been studied in detail. Therefore, we aimed to assess the prevalence of multimorbidity and its association with mortality in type 1 diabetes.
methodsThis observational follow-up study includes 4069 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy study. The prevalence of multimorbidity (coexistence of two or more chronic conditions) was based on 32 conditions at baseline. Conditions were grouped into three subcategories: vascular comorbidities, autoimmune disorders, and other conditions. Hazard ratios (HR) for all-cause mortality were calculated.
resultsThe prevalence of multimorbidity was 60.4% and increased with age and especially diabetes duration. Multimorbidity was associated with increased risk of mortality, HR 6.0 (95% CI 4.6-7.8), p < 0.001. The HR for mortality increased by each additional condition and was 37.9 (95% CI 25.7-56.0) in those with ≥eight conditions. Vascular comorbidities and other conditions were associated with increased mortality, HRs 5.9 (4.4-7.9) and 3.8 (2.4-5.9), p < 0.001, separately, and in combination, HR 11.2 (8.3-15.2), p < 0.001. Autoimmune disorders did not influence mortality.
conclusionsMultimorbidity in type 1 diabetes is common and is associated with increased mortality. Comprehensive evaluation of all additional conditions is needed to tailor treatment individually.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.